Molecular MRI of Inflammation in Atherosclerosis

Current Cardiovascular Imaging Reports

Volumn 5, Issue 1, 2012, Pages 60-68

  te Boekhorst, Bernard C ^a   van Tilborg, Geralda A ^b   Strijkers, Gustav J ^a   Nicolay, Klaas ^a  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Activatable contrast agent; Activated platelets; Apoptosis; Atherosclerosis; Cellular MRI; Fibrin; Gadolinium; HDL like nanoparticle; Inflammation; Integrins; Iron oxide; Liposome; Macrophages; Micelle; MMPs; Molecular MRI; Myeloperoxidase; Nanoparticles; Ox LDL; Perfluorocarbon nanoparticle; USPIO; Vascular adhesion molecules

Indexed keywords

EID: 84862492756     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-011-9114-4     Document Type: Review

References (54)

1. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J. 1999; 138: S419-20.
2. Leuschner F, Nahrendorf M. Molecular imaging of coronary atherosclerosis and myocardial infarction: considerations for the bench and perspectives for the clinic. Circ Res. 2011; 108: 593-606.
3. Briley-Saebo KC, Shaw PX, Mulder WJ, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation. 2008; 117: 3206-15.
4. Hak S, Sanders HM, Agrawal P, et al. A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm. 2009; 72: 397-404.
5. Ide M, Kuwamura M, Kotani T, et al. Effects of gadolinium chloride (GdCl(3)) on the appearance of macrophage populations and fibrogenesis in thioacetamide-induced rat hepatic lesions. J Comp Pathol. 2005; 133: 92-102.
6. Pedersen M. Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn Reson Imaging. 2007; 25: 881-3.
7. Briley-Saebo KC, Cho YS, Shaw PX, et al. Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. J Am Coll Cardiol. 2011; 57: 337-47.
8. McAteer MA, Akhtar AM, von Zur MC, et al. An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. Atherosclerosis. 2010; 209: 18-27.
9. Akhtar AM, Schneider JE, Chapman SJ, et al. In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using non-invasive magnetic resonance molecular imaging. PLoS One. 2010; 5: e12800.
10. Kelly KA, Allport JR, Tsourkas A, et al. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res. 2005; 96: 327-36.
11. Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006; 114: 1504-11.
12. Alsaid H, De SG, Bourdillon MC, et al. Biomimetic MRI contrast agent for imaging of inflammation in atherosclerotic plaque of ApoE-/- mice: a pilot study. Invest Radiol. 2009; 44: 151-8.
13. Sluimer JC, Daemen MJ. Novel concepts in atherogenesis: angiogenesis and hypoxia in atherosclerosis. J Pathol. 2009; 218: 7-29.
14. Dunmore BJ, McCarthy MJ, Naylor AR, et al. Carotid plaque instability and ischemic symptoms are linked to immaturity of microvessels within plaques. J Vasc Surg. 2007; 45: 155-9.
15. Takaya N, Yuan C, Chu B, et al. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation. 2005; 111: 2768-75.
16. Yuan C, Kerwin WS, Ferguson MS, et al. Contrast-enhanced high resolution MRI for atherosclerotic carotid artery tissue characterization. J Magn Reson Imaging. 2002; 15: 62-7.
17. Calcagno C, Mani V, Ramachandran S, et al. Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) of atherosclerotic plaque angiogenesis. Angiogenesis. 2010; 13: 87-99.
18. Barkhausen J, Ebert W, Heyer C, et al. Detection of atherosclerotic plaque with Gadofluorine-enhanced magnetic resonance imaging. Circulation. 2003; 108: 605-9.
19. Meding J, Urich M, Licha K, et al. Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with gadofluorine M. Contrast Media Mol Imaging. 2007; 2: 120-9.
20. Sirol M, Moreno PR, Purushothaman KR, et al. Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability. Circ Cardiovasc Imaging. 2009; 2: 391-6.
21. Cai K, Caruthers SD, Huang W, et al. MR molecular imaging of aortic angiogenesis. JACC Cardiovasc Imaging. 2010; 3: 824-32.
22. Winter PM, Caruthers SD, Allen JS, et al. Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med. 2010; 64: 369-76.
23. Schmitz SA. Iron-oxide-enhanced MR imaging of inflammatory atherosclerotic lesions: overview of experimental and initial clinical results. Rofo. 2003; 175: 469-76.
24. Schmitz SA, Taupitz M, Wagner S, et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J Magn Reson Imaging. 2001; 14: 355-61.
25. Te Boekhorst BC, Bovens SM, Nederhoff MG, et al. Negative MR contrast caused by USPIO uptake in lymph nodes may lead to false positive observations with in vivo visualization of murine atherosclerotic plaque. Atherosclerosis. 2010; 210: 122-9.
26. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003; 107: 2453-8.
27. Tang T, Howarth SP, Miller SR, et al. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke. 2006; 37: 2266-70.
28. Tang TY, Howarth SP, Miller SR, et al. The ATHEROMA (atorvastatin therapy: effects on reduction of macrophage activity) study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol. 2009; 53: 2039-50.
29. Amirbekian V, Lipinski MJ, Briley-Saebo KC, et al. Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A. 2007; 104: 961-6.
30. Lipinski MJ, Frias JC, Amirbekian V, et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. JACC Cardiovasc Imaging. 2009; 2: 637-47.
31. Li D, Patel AR, Klibanov AL, et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging. 2010; 3: 464-72.
32. Maiseyeu A, Mihai G, Kampfrath T, et al. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J Lipid Res. 2009; 50: 2157-63.
33. Te Boekhorst BC, Bovens SM, Rodrigues-Feo J, et al. Characterization and in vitro and in vivo testing of CB2-receptor- and NGAL-targeted paramagnetic micelles for molecular MRI of vulnerable atherosclerotic plaque. Mol Imaging Biol. 2010; 12: 635-51.
34. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature. 2005; 434: 782-6.
35. Te Boekhorst BC, Bovens SM, van de Kolk CW, et al. The time window of MRI of murine atherosclerotic plaques after administration of CB2 receptor targeted micelles: inter-scan variability and relation between plaque signal intensity increase and gadolinium content of inversion recovery prepared versus non-prepared fast spin echo. NMR Biomed. 2010; 23: 939-51.
36. Chen W, Vucic E, Leupold E, et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis. Contrast Media Mol Imaging. 2008; 3: 233-42.
37. Cormode DP, Briley-Saebo KC, Mulder WJ, et al. An ApoA-I mimetic peptide high-density-lipoprotein-based MRI contrast agent for atherosclerotic plaque composition detection. Small. 2008; 4: 1437-44.
38. Skajaa T, Cormode DP, Falk E, et al. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30: 169-76.
39. Kamat M, El-Boubbou K, Zhu DC, et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages. Bioconjug Chem. 2010; 21: 2128-35.
40. Schafers M, Schober O, Hermann S. Matrix-metalloproteinases as imaging targets for inflammatory activity in atherosclerotic plaques. J Nucl Med. 2010; 51: 663-6.
41. Lancelot E, Amirbekian V, Brigger I, et al. Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol. 2008; 28: 425-32.
42. Te Boekhorst BC, Bovens SM, Hellings WE, et al. Molecular MRI of murine atherosclerotic plaque targeting NGAL: a protein associated with unstable human plaque characteristics. Cardiovasc Res. 2011; 89: 680-8.
43. Brennan ML, Reddy A, Tang WH, et al. Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death. Circulation. 2010; 122: 70-9.
44. •• Ronald JA, Chen JW, Chen Y, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation. 2009; 120: 592-9. In vivo potential of activatable contrast agents for visualization of enzyme activity in plaques with MRI.
45. van Tilborg GA, Vucic E, Strijkers GJ, et al. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug Chem. 2010; 21: 1794-803.
46. Burtea C, Laurent S, Lancelot E, et al. Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm. 2009; 6: 1903-19.
47. Johansson LO, Bjornerud A, Ahlstrom HK, et al. A targeted contrast agent for magnetic resonance imaging of thrombus: implications of spatial resolution. J Magn Reson Imaging. 2001; 13: 615-8.
48. Ta HT, Prabhu S, Leitner E, et al. Enzymatic single-chain antibody tagging: a universal approach to targeted molecular imaging and cell homing in cardiovascular disease. Circ Res. 2011, Epub ahead of print.
49. Von zur Muhlen C, Von Elverfeldt D, Moeller JA, et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation. 2008; 118: 258-67.
50. •• Spuentrup E, Botnar RM, Wiethoff AJ, et al. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur Radiol. 2008; 18: 1995-2005. In vivo clinical applicability of small gadolinium-based fibrin-targeted contrast agent.
51. Morawski AM, Winter PM, Yu X, et al. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn Reson Med. 2004; 52: 1255-62.
52. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J Magn Reson. 2000; 143: 79-87.
53. • Winter PM, Cai K, Chen J, et al. Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med. 2006; 56: 1384-8. An example of fibrin-targeting with a paraCEST contrast agent with possible transfer to the clinic.
54. • Taboada E, Rodriguez E, Roig A, et al. Relaxometric and magnetic characterization of ultrasmall iron oxide nanoparticles with high magnetization. Evaluation as potential T1 magnetic resonance imaging contrast agents for molecular imaging. Langmuir. 2007; 23: 4583-8. Description of the T1 contrast properties of iron oxide-based nanoparticles, which have less toxicity issues when compared to gadolinium-based nanoparticles. Positive contrast caused by shortened T1 is not masked by susceptibility artifacts and area of contrast uptake will not be overestimated as is the case with T2* contrast.